Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Research

Palvella Therapeutics
Research

Palvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN Rapamycin

June 24, 2025June 23, 2025 - by Timothy Alexander

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has successfully completed enrollment in the Phase 3 SELVA clinical trial of QTORINâ„¢ 3.9% rapamycin anhydrous gel, a potential breakthrough treatment for …

Palvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN Rapamycin Read More

Aclaris Therapeutics
Research

Aclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052

June 23, 2025June 23, 2025 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has launched a Phase 1a/1b clinical program to evaluate the safety and efficacy of ATI-052, an investigational bispecific anti-TSLP/IL-4R antibody that could …

Aclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052 Read More
DNA
National / Research

FDA Investigates Clinical Trials Sending U.S. DNA Overseas

June 23, 2025June 22, 2025 - by Maryann Pugh

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has initiated an immediate review of clinical trials involving the international transfer of Americans’ living cells for genetic engineering and subsequent …

FDA Investigates Clinical Trials Sending U.S. DNA Overseas Read More

PleoPharma
Research

PleoPharma Presents Promising Phase 2b Data on PP-01 for Cannabis Withdrawal

June 20, 2025June 19, 2025 - by Timothy Alexander

PHOENIXVILLE, PA — PleoPharma, Inc. shared encouraging findings from its Phase 2b clinical trial of PP-01, a novel treatment for Cannabis Withdrawal Syndrome (CWS), during the 2025 annual meeting of …

PleoPharma Presents Promising Phase 2b Data on PP-01 for Cannabis Withdrawal Read More
Ocugen
Research

Ocugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt Disease

June 17, 2025June 17, 2025 - by Timothy Alexander

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase 2/3 pivotal confirmatory trial of OCU410ST, an innovative …

Ocugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt Disease Read More

National Comprehensive Cancer Network
Research

Telehealth Program Improves Quality of Life for Older Cancer Patients, Study Finds

June 15, 2025June 14, 2025 - by Timothy Alexander

PLYMOUTH MEETING, PA — A new study published in the June 2025 issue of JNCCN—Journal of the National Comprehensive Cancer Network highlights the life-changing impact of a telehealth-based care program …

Telehealth Program Improves Quality of Life for Older Cancer Patients, Study Finds Read More
Panavance Therapeutics
Research

Panavance Therapeutics Reports Promising Phase 1 Results for Pancreatic Cancer Therapy

June 14, 2025June 13, 2025 - by Timothy Alexander

BERWYN, PA — Panavance Therapeutics Inc. has shared promising interim findings from its ongoing Phase 1 clinical trial investigating misetionamide (GP-2250), a novel second-line therapy for advanced pancreatic cancer. These …

Panavance Therapeutics Reports Promising Phase 1 Results for Pancreatic Cancer Therapy Read More

Lungpacer Medical
Research

Lungpacer Medical Publishes Landmark Findings on AeroPace System in Critical Care

June 13, 2025June 12, 2025 - by Timothy Alexander

EXTON, PA — Lungpacer Medical, Inc. has announced pivotal results from the RESCUE-3 trial, published in the American Journal of Respiratory and Critical Care Medicine, showcasing the groundbreaking benefits of …

Lungpacer Medical Publishes Landmark Findings on AeroPace System in Critical Care Read More
Teleflex Incorporated
Research

Teleflex Study Shows 70.5% Reduction in CLABSI with Antimicrobial CVCs

June 13, 2025June 12, 2025 - by Timothy Alexander

WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has announced findings from a new multinational study demonstrating the efficacy of its Arrowâ„¢ Chlorhexidine-Impregnated Central Venous Catheters (CVCs) in reducing central line-associated …

Teleflex Study Shows 70.5% Reduction in CLABSI with Antimicrobial CVCs Read More
Research

Aclaris Therapeutics Launches Phase 2 Trial for Promising Atopic Dermatitis Treatment

June 2, 2025June 2, 2025 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced the initiation of a Phase 2 trial for its investigational drug bosakitug (ATI-045), targeting moderate-to-severe atopic dermatitis (AD). This randomized, …

Aclaris Therapeutics Launches Phase 2 Trial for Promising Atopic Dermatitis Treatment Read More

Posts pagination

1 2 … 13 Next

Trending News

  • Security Guard Accused of Brutal Assault That Left Man Unconscious Outside Huntingdon Valley Restaurant

  • Vanguard Survey Highlights Emotional and Time-Saving Benefits of Personalized Financial Advice

  • Thieves Target South Heidelberg Shed, Steal Off-Road Vehicles and Power Equipment in Bold Overnight Heist

  • Elderly Woman Attacked and Robbed in Center City — Police Urge Public’s Help to Catch Suspect

  • Major Paving Project on Route 3 in West Goshen to Bring Traffic Delays Next Week — Here’s What You Need to Know

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Kris Michael Sanchez

Security Guard Accused of Brutal Assault That Left Man Unconscious Outside Huntingdon Valley Restaurant

July 12, 2025July 12, 2025

Yamaha Raptor

Thieves Target South Heidelberg Shed, Steal Off-Road Vehicles and Power Equipment in Bold Overnight Heist

July 12, 2025July 12, 2025

Robbery suspect

Elderly Woman Attacked and Robbed in Center City — Police Urge Public’s Help to Catch Suspect

July 12, 2025July 12, 2025

Copyright © 2025 MyChesCo.